June 28, 2001

FORT WORTH, Texasâ?? Relying on cholesterol levels alone to pinpoint whoâ??s at risk for heart disease may not be enough, according to a paper to be published in this weekâ??s New England Journal of Medicine.

Study authors, including researchers at the University of North Texas Health Science Center, measured C-reactive protein levels, along with cholesterol levels, to gain insight into who can benefit from preventive drug therapy. The study showed that statin drug therapy may help prevent coronary events in people who have elevated C-reactive protein values but whose baseline levels of LDL cholesterol are considered normal. If confirmed in additional studies, the results may provide persuasive evidence for measuring both C-reactive protein and blood lipids in healthy adults.

Results are based on further analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a primary prevention trial of Merck and Co.â??s cholesterol-lowering drug Mevacorâ?? (lovastatin). Researchers studied whether study participants with elevated C-reactive protein levels but no hyperlipidema benefited from taking the drug.

The AFCAPS/TexCAPS was conducted between 1990 and 1998 at the UNT Health Science Center in Fort Worth and the Wilford Hall Medical Center at Lackland Air Force Base in San Antonio.

Michael Clearfield, D.O., chief of internal medicine at the UNT Health Science Center, served as principal investigator for the TexCAPS study. Stephen Weis, D.O., professor of internal medicine, was a co-investigator for the study.

“Half the people who develop heart disease have a cholesterol level that is considered to be normal and many do not have other identified risk factors,” said Dr. Clearfield. “We now have a way to better identify apparently healthy people who can benefit from preventive treatment.”

AFCAPS/TexCAPS included 6,605 participants whose average cholesterol levels were 221 at baseline and had average HDL cholesterol levels of 37. Between 1990 and 1998, a total of 2,868 participants took part in the study through the TexCAPS clinics located on the health science centerâ??s campus in Fort Worthâ??s cultural district. The remaining participants were studied in San Antonio.


John Licciardone Hsc Fort Worth Fc
eHealth interventions could help African-American patients in battle with chronic pain

By Steven Bartolotta The PRECISION Pain Research Registry at the University of North Texas Health Science Center in Fort Worth has identified important racial disparities in pain management that became more evident during the COVID-19 pandemic. Its study recently published in the special COVID...Read more

Jun 14, 2021

Diana Cervantes. Assistant Professor Biostatistics & Epidemiology
Dr. Diana Cervantes named among Fort Worth’s ‘most influential’ for public health service during the pandemic

By Sally Crocker Dr. Diana Cervantes has spent the last year keeping people informed and updated on all things coronavirus, and now she’s being recognized as one of Fort Worth Inc.’s “400 Most Influential People” for helping protect the community’s health during the pandemic. Dr....Read more

Jun 8, 2021

Opal Lee photo by Rodger Mallison/Fort Worth Star-Telegram
Celebrating Juneteenth

By Diane Smith-Pinckney On June 19 1865, Major General Gordan Granger marched into Galveston with a critical message: “The people of Texas are informed that, in accordance with a Proclamation from the Executive of the United States, all slaves are free.”  This was the opening se...Read more

Jun 8, 2021

Dr. Scott Walters
The realities of ‘breaking bad’ and how one HSC researcher is attacking the opioid crisis

By Sally Crocker He didn’t know it at the time, but when Dr. Scott Walters was growing up in San Diego in the mid 1980s, a next-door neighbor was concealing a homemade meth lab just across the fence and mere steps away from his bedroom window. For quite some time, concerned parents in his fa...Read more

Jun 8, 2021